ClinicalTrials.gg
TerminatedNCT03430791Updated Feb 2, 2023Results posted

Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma

A Phase 2 interventional study of Nivolumab 240 mg IV and Nivolumab 3 mg/kg in Recurrent Glioblastoma, sponsored by Baptist Health South Florida. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-02.

Sponsored by Baptist Health South Florida · Phase 2, Interventional, and Treatment

Why this study was terminated
Study Investigator/Sponsor decided to end enrollment earlier.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 20 studies testing nivolumab in Glioblastoma — 3 open to participants now, 11 under way, none of them phase 3. Nivolumab · Glioblastoma.

Enrollment
18th of 20
5 · median 36
Started
2018
with 3 others
Phase 2
12 of 20
2 open now
Registered
8th of 20
by date
Lead sponsor
1 of 20
Baptist Health South Florida

Among the 20 studies testing nivolumab in Glioblastoma, this one is the 18th largest by enrollment, is one of 4 that started in 2018, is one of 12 in phase 2, and was the 8th registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

3 of the 20 studies testing nivolumab in Glioblastoma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 340 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing nivolumab in Glioblastoma, or all of them as a file.
02

Study summary

Phase I/II trial in which participants with recurrent glioblastoma will receive a combination of tumor treating fields(portable device), nivolumab with or without ipilimumab.

Read the detailed description

Phase I/II trial in which participants with recurrent glioblastoma will receive a combination of tumor treating fields(portable device), nivolumab with or without ipilimumab.

The NovoTTF200A (OptuneTM) device is worn continuously for a goal of 75% or more of the time, ranging from at least 18 hours daily uninterrupted or 22 hours daily with 2-3 days off monthly. Therapy is planned for approximately 24 months.

Infusions with nivolumab will start within 1 week of study start. Ipilimumab will either start with the second nivolumab infusion or at after tumor progression. Nivolumab is infused intravenously at 240 mg once every 2 weeks with or without ipilimumab for a maximum of 24 months. Ipilimumab is dosed at 1 mg/kg once every 6 weeks for a maximum of 4 doses (24 weeks). Infusions will continue until maximum doses are completed or there is confirmed tumor progression, intolerable adverse effects or withdrawal of consent.

03

Conditions studied

  • Recurrent Glioblastoma

Browse trials for

Keywords

  • recurrent glioblastoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed World Health Organization Grade IV glioblastoma with supratentorial distribution.
  • Unequivocal evidence of progressive disease on contrast-enhanced brain CT or MRI as defined by Response Assessment in Neuro-Oncology (RANO) criteria, or documented recurrent glioblastoma on .
  • based on RANO criteria.
  • Prior therapies including radiation and temozolomide.
  • Any number of recurrences are allowed. Resection of recurrent glioblastoma is not considered a prior treatment.
  • From the projected start date of study treatment, the following periods must have elapsed: 4 weeks from any agent, 4 weeks from cytotoxic therapy (except 23 days for temozolomide and 6 weeks from nitrosoureas), or 4 weeks from any other antibodies or any other antineoplastic therapies.
  • Must be at least 12 weeks from radiotherapy or progression outside of the high-dose radiation target volume or unequivocal evidence of progressive tumor on biopsy.
  • All adverse events Grade > 1 related to prior therapies (chemotherapy, radiotherapy, and/or surgery) must be resolved, except for alopecia.
  • Performance Status (KPS) ≥ 60
  • Adequate organ and marrow function as defined below, all screening labs should be performed within 14 days of treatment initiation:

    • ≥ 1,000/mcL
    • ≥100,000/mcL
    • > 8.0 mg/dL
    • total ≤ 2.0 x
    • (SGOT)/ALT (SGPT) ≤ 2.5 × upper limit of normal
    • creatinine or ≥ 60 mL/min/1.73 m2 for creatinine >ULN
  • dose must be stable or decreasing for at least 5 days prior to enrollment.
  • Nivolumab and ipilimumab are potentially teratogenic or abortifacient. Women of and men must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to entry and for the duration of study. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Male subjects should agree to use adequate method of contraception starting with the first dose through 7 months after the last dose of therapy.
  • Brain CT or MRI within 14 days prior to start of study drug.
  • Archival tissue for evaluation of correlative objectives (if available).
  • Ability to understand and the willingness to provide written .

Exclusion criteria

Exclusion Criteria:

  • Infratentorial disease.
  • Bevacizumab within 2 months of enrollment. Prior use of ipilimumab or other inhibitor or prior TTFields.
  • Tumors with known IDH1 (isocitrate dehydrogenase 1) or IDH2 mutations as determined by immunohistochemistry for the IDH1 R132H variant or by direct sequencing. IDH1/2-mutant gliomas have a prolonged overall survival rate compared to IDH1/2-wildtype gliomas, indicating distinct natural history.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab or ipilimumab or their .
  • Current or planned participation in a study of an agent or using an investigational device.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements.
  • Active or life-threatening infection requiring intravenous or >2 weeks of systemic therapy.
  • Prior stereotactic radiotherapy, convection enhanced delivery (CED) or brachytherapy requires a to confirm radiographic progression is consistent with progressive tumor and not treatment-related necrosis unless the recurrent lesion is outside of any prior high-dose radiation target volume or distant from the prior CED or brachytherapy site.
  • There is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these agents, so breastfeeding must be discontinued by enrollment on study.
  • Uncontrolled or AIDS is not allowed. Patients with known history of HIV but with undetectable viral load on antiretroviral therapy are allowed.
  • Congestive heart failure, myocardial infarction, or hemorrhagic/ischemic stroke in the last 3 months.
  • Active illicit drug use or diagnosis of alcoholism
  • Known additional that is progressing or requires active treatment within 3 years of start of study drug. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ cervical cancer or other in situ malignancy that has undergone potentially curative therapy and/or with >90% probability of survival beyond 5 years.
  • Any surgery (not including minor diagnostic procedures such as lymph node biopsy) within 2 weeks of start of treatment. Incomplete recovery from any side effects of previous procedures is also exclusionary.
  • Any significant disorders expected to impact multiple or internal organs, excluding mild eczema or autoimmune thyroiditis treated with thyroidectomy and requiring systemic or immunomodulatory therapy.
  • Any implanted programmable cranial device, including reprogrammable ventriculoperitoneal shunt (VPS) or cochlear implants, that precludes use of TTFields (Optune) therapy.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Nivolumab Monotherapy

    Nivolumab 240 mg IV every 2 weeks for maximum of 24 months. TTF (Optune) for max of 24 months

    Drug: Nivolumab 240 mg IV · Device: NovoTTF200A (Optune)

  • Experimental
    Nivolumab+Ipilimumab

    Nivolumab 3 mg/kg IV with ipilimumab then 240 mg every 2 weeks for maximum of 24 months. Ipilimumab 1 mg/kg IV every 6 weeks maximum of 4 times. NovoTTF200A (Optune) TTF for maximum 24 months

    Drug: Nivolumab 240 mg IV · Drug: Nivolumab 3 mg/kg · Drug: Ipilimumab 1 mg/kg · Device: NovoTTF200A (Optune)

Interventions

  • Nivolumab IV 240mg IV every 2 weeks for maximum of 24 months.

    Also known as: Nivolumab Monotherapy

  • DrugNivolumab 3 mg/kg

    Drug page: Nivolumab

    Nivolumab IV 3mg/kg every 2 weeks for maximum of 24 months.

    Also known as: Nivolumab+Ipilimumab

  • DrugIpilimumab 1 mg/kg

    Drug page: Ipilimumab

    Ipilimumab IV 1 mg/kg every 6 weeks for maximum of 4 doses.

    Also known as: Nivolumab+Ipilimumab

  • DeviceNovoTTF200A (Optune)

    A device to be worn continuously for a goal of 75% of the time, ranging from 18 hours daily nonstop or 22 hours daily with 2-3 days off monthly.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate According to Modified iRANO Criteria

    Objective response rate is the proportion of patients whose best overall response per modified immunotherapy response assessment in neuro-oncology (iRANO) criteria is complete (CR) or partial (PR) after at least 6 weeks from start of therapy

    Time frame: 2 years

Secondary outcomes

  1. Objective Response Rate (ORR) by Standard RANO Criteria

    Objective response rate is the proportion of patients whose best overall response per response assessment in neuro-oncology (RANO) criteria is complete (CR) or partial (PR) after at least 6 weeks from start of therapy

    Time frame: 2 years

  2. Progression Free Survival (PFS)

    The length of time that a participant lives with the disease but it does not get worse.

    Time frame: 2 years

  3. Number of Toxicities

    Total number of toxicities as defined by AEs that attributed as probable or possibly related to the study drug across all study subjects.

    Time frame: Up to 2 years

  4. Rate of Treatment Compliance

    Percent of participants who have a compliance rate above the 75% goal for tumor treating fields (TTFields) therapy via the NovoTTF200A (OptuneTM). Daily compliance rates for using the device are averaged (mean ± stdev) over the 28-31 days of the month.

    Time frame: Monthly for up to 2 years

  5. Discontinuation Rate of Any Component of Therapy

    Proportion of participants who discontinued therapy. Reasons for discontinuation also will be noted.

    Time frame: Up to 2 years

  6. Change in Quality of Life From Baseline Using the Functional Assessment of Cancer Therapy-Brain (FACT-Br)

    FACT-Br is a validated self-report tool measuring general quality of life (QOL) that assesses symptoms or problems associated with CNS tumors across 5 scales. FACT-Br yields data about total QOL, as well as dimensions of disease specific physical, social/family, emotional, and functional well-being. The tool contains 20 items using a 5-point Likert scale. A higher score indicates better QOL, ranging from 0 (lowest) to 92 (highest). Median percent change between first and last measurement provided, with negative percent change indicating a decline in function.

    Time frame: Up to 2 years

  7. Change in Quality of Life From Baseline Using the Functional Assessment of Cancer Therapy-General (FACT-G)

    FACT-G is a validated self-report tool measuring general quality of life (QOL) that assesses symptoms or problems associated with any tumors. The tool contains 33 items using a 5-point Likert scale. A higher score indicates better QOL, ranging from 0 (lowest) to 108 (highest). Median percent change between first and last measurement provided, with negative percent change indicating a decline in function.

    Time frame: Up to 2 years

07

Results

Posted Feb 2, 2023
Limitations and caveats
Did not accrue the target number of participants needed to achieve target power and statistically reliable results.

Participant flow

Participant flow — Overall Study
MilestoneNivolumab MonotherapyNivolumab+Ipilimumab
Started40
Completed40
Not completed00

Outcome measures

PrimaryObjective Response Rate According to Modified iRANO Criteria

Objective response rate is the proportion of patients whose best overall response per modified immunotherapy response assessment in neuro-oncology (iRANO) criteria is complete (CR) or partial (PR) after at least 6 weeks from start of therapy

Time frame:
2 years
Reported as:
Count of participants · Participants
Objective Response Rate According to Modified iRANO Criteria
ParticipantsNivolumab MonotherapyNivolumab+Ipilimumab
Objective Response Rate According to Modified iRANO Criteria0—
SecondaryObjective Response Rate (ORR) by Standard RANO Criteria

Objective response rate is the proportion of patients whose best overall response per response assessment in neuro-oncology (RANO) criteria is complete (CR) or partial (PR) after at least 6 weeks from start of therapy

Time frame:
2 years
Reported as:
Count of participants · Participants
Objective Response Rate (ORR) by Standard RANO Criteria
ParticipantsNivolumab MonotherapyNivolumab+Ipilimumab
Objective Response Rate (ORR) by Standard RANO Criteria0—
SecondaryProgression Free Survival (PFS)

The length of time that a participant lives with the disease but it does not get worse.

Time frame:
2 years
Reported as:
Mean · days
Progression Free Survival (PFS)
daysNivolumab MonotherapyNivolumab+Ipilimumab
Progression Free Survival (PFS)62.5 ± 16.1—
SecondaryNumber of Toxicities

Total number of toxicities as defined by AEs that attributed as probable or possibly related to the study drug across all study subjects.

Time frame:
Up to 2 years
Reported as:
Number · adverse events
Number of Toxicities
adverse eventsNivolumab MonotherapyNivolumab+Ipilimumab
Number of Toxicities13—
SecondaryRate of Treatment Compliance

Percent of participants who have a compliance rate above the 75% goal for tumor treating fields (TTFields) therapy via the NovoTTF200A (OptuneTM). Daily compliance rates for using the device are averaged (mean ± stdev) over the 28-31 days of the month.

Time frame:
Monthly for up to 2 years
Reported as:
Mean · percent of participants compliant
Rate of Treatment Compliance
percent of participants compliantNivolumab MonotherapyNivolumab+Ipilimumab
Rate of Treatment Compliance75 ± 12—
SecondaryDiscontinuation Rate of Any Component of Therapy

Proportion of participants who discontinued therapy. Reasons for discontinuation also will be noted.

Time frame:
Up to 2 years
Reported as:
Count of participants · Participants
Discontinuation Rate of Any Component of Therapy
ParticipantsNivolumab MonotherapyNivolumab+Ipilimumab
Discontinuation Rate of Any Component of Therapy4—
SecondaryChange in Quality of Life From Baseline Using the Functional Assessment of Cancer Therapy-Brain (FACT-Br)

FACT-Br is a validated self-report tool measuring general quality of life (QOL) that assesses symptoms or problems associated with CNS tumors across 5 scales. FACT-Br yields data about total QOL, as well as dimensions of disease specific physical, social/family, emotional, and functional well-being. The tool contains 20 items using a 5-point Likert scale. A higher score indicates better QOL, ranging from 0 (lowest) to 92 (highest). Median percent change between first and last measurement provided, with negative percent change indicating a decline in function.

Time frame:
Up to 2 years
Reported as:
Median · percentage of change
Change in Quality of Life From Baseline Using the Functional Assessment of Cancer Therapy-Brain (FACT-Br)
percentage of changeNivolumab MonotherapyNivolumab+Ipilimumab
Change in Quality of Life From Baseline Using the Functional Assessment of Cancer Therapy-Brain (FACT-Br)-22 (-25 to 3)—
SecondaryChange in Quality of Life From Baseline Using the Functional Assessment of Cancer Therapy-General (FACT-G)

FACT-G is a validated self-report tool measuring general quality of life (QOL) that assesses symptoms or problems associated with any tumors. The tool contains 33 items using a 5-point Likert scale. A higher score indicates better QOL, ranging from 0 (lowest) to 108 (highest). Median percent change between first and last measurement provided, with negative percent change indicating a decline in function.

Time frame:
Up to 2 years
Reported as:
Median · percentage of change
Change in Quality of Life From Baseline Using the Functional Assessment of Cancer Therapy-General (FACT-G)
percentage of changeNivolumab MonotherapyNivolumab+Ipilimumab
Change in Quality of Life From Baseline Using the Functional Assessment of Cancer Therapy-General (FACT-G)-13 (-28 to 3)—

Adverse events

Collected over 18 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nivolumab Monotherapy2/4 (50%)0/4 (0%)4/4 (100%)
Nivolumab+Ipilimumab———
Most frequent other events
Showing 10 of 15
Most frequent other events
EventNivolumab MonotherapyNivolumab+Ipilimumab
Scalp rashSkin and subcutaneous tissue disorders2/4—
WeaknessGeneral disorders2/4—
FatigueGeneral disorders1/4—
Dry mouthGastrointestinal disorders1/4—
DysarthriaNervous system disorders1/4—
FallInjury, poisoning and procedural complications1/4—
Flank painMusculoskeletal and connective tissue disorders1/4—
HemiplegiaNervous system disorders1/4—
HyperthyroidEndocrine disorders1/4—
Pituitary disorderEndocrine disorders1/4—

Baseline characteristics

No participants with prior PD1/PDL1 checkpoint inhibitor were enrolled, thus no participants were assigned to the Nivolumab+Ipilimumab arm.

Age, Continuous
Age, Continuous(Years)Nivolumab MonotherapyNivolumab+IpilimumabTotal
Median65 (57 to 80)—65 (57 to 80)
Sex: Female, Male
Sex: Female, Male(Participants)Nivolumab MonotherapyNivolumab+IpilimumabTotal
Female202
Male202
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nivolumab MonotherapyNivolumab+IpilimumabTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White303
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Nivolumab MonotherapyNivolumab+IpilimumabTotal
United States404
08

Study locations

1 site
  • Miami Cancer Institute at Baptist Health, Inc.
    Miami, Florida 33176, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2018 to primary completion in May 2020, 17 months.

Results were first posted in Feb 2023, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2018
First posted
Feb 13, 2018
StartActual
Dec 5, 2018
Primary completionActual
May 29, 2020
CompletionActual
Jan 27, 2021
Results first posted
Feb 2, 2023
Last update
Feb 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03430791
Lead sponsor
Baptist Health South Florida
Responsible party
Sponsor
First posted
Feb 13, 2018
Start date
Dec 5, 2018
Primary completion
May 29, 2020
Completion
Jan 27, 2021
Results posted
Feb 2, 2023
Last update
Feb 2, 2023

Study contacts

Yazmin Odia
principal investigator · Miami Cancer Institute at Baptist Health, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion